Treatment of type 2 diabetes mellitus (DM2) is an important task of modern medicine against the background of the inexorable spread of the disease. Recently, the possibilities of glucose-lowering pharmacotherapy have significantly expanded due to a deepening of understanding of the pathophysiological mechanisms of the disease. The importance of the incretin system in the regulation of carbohydrate metabolism, a target for incretin-directed therapy, is discussed. The class of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors, gliptins) refers to drugs with incretin activity. The mechanisms of action of DPP-4 inhibitors are revealed, and the advantages of drugs in this group are emphasized. Several DPP-4 inhibitors are registered in the Russian Federation: alogliptin, vildagliptin, gemigliptin, gosogliptin, linagliptin, saxagliptin, sitagliptin, evogliptin. The article is devoted to the selection of the optimal drug from the DPP-4 group. The appearance on the market of a new Russian drug from this group of DPP-4 inhibitors, evogliptin, will make it possible to provide DM2 patients with modern, effective, affordable and high-quality treatment. The results of clinical studies of the effectiveness and safety of evogliptin are presented.

Keywords: evogliptin, DPP-4 inhibitors, glycated hemoglobin, hypoglycemia, type 2 diabetes mellitus